Edgewise reports Q4 net loss $50.2M ($0.47/sh); cash $530M; key trial readouts in 2026

Edgewise Therapeutics, Inc.

2025-FY EPS reported -$1.63

Net loss for Q4 2025 was $50.2M ($0.47/sh) vs $40.7M ($0.39/sh) in prior quarter; no revenue.
Cash, cash equivalents and marketable securities total $530.1M as of Dec 31, 2025.
GRAND CANYON top-line results for sevasemten in Becker expected Q4 2026; NDA submission H1 2027.
CIRRUS-HCM Part D 12-week data for EDG-7500 in HCM expected H1 2026; Phase 3 start H2 2026.
EDG-15400 Phase 1 healthy adult data H1 2026; Phase 2 in HFpEF planned H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.